Rabindranath Bera1,#, Yotaro Ochi2,3, Ying-Jung Huang1, Ming-Chung Kuo1,4, Kenichi Yoshida5, Seishi Ogawa2, Lee-Yung Shih1,4,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070259
- 30 December 2025
Abstract Background: Breakpoint Cluster Region-Abelson (BCR::ABL1) fusion protein is essential in the pathogenesis of chronic myeloid leukemia (CML); however, the chronic-to-blast phase transformation remains elusive. We identified novel kinesin light chain 2 (KLC2) mutations in CML-myeloid blast phase patients. We aimed to examine the functional role of KLC2 mutations in leukemogenesis. Methods: To evaluate the biological role of KLC2 mutants (MT) in CML cells, we expressed KLC2-MT in different human CML cell lines harboring BCR::ABL1 and performed immunoblot, immunofluorescence, cell proliferation, differentiation, and apoptosis; Tyrosine kinase inhibitor (TKI)-drug activities; and clonogenic assays for in vitro functional analyses. We co-expressed KLC2-MT… More >